This article was reviewed by Darragh O’Carroll, MD. Oral vs. Injectable Semaglutide: Effectiveness & Side Effects Key ...

A drug most often prescribed for diabetes and obesity might soon be prescribed to curb one of the world’s hardest to quit ...

China's Innovent Biologics saidon Monday its GLP-1 injection led to more weight loss and better control of blood sugar in ...

Novo Nordisk today presented new data from the OASIS 4 phase 3 trial that explored a variety of patients and hypotheses, ...

A new analysis finds that the heart-protecting benefits of semaglutide are largely independent of its weight loss effects.

The Company’s investigational small moleculeglucagon-like peptide-1 ('GLP-1”) receptor agonist ('RA”), BMF-650, demonstrated potent weight loss and good tolerability in obese cynomolgus monkeys A ...

Semaglutide, the diabetes drug at the center of a global boom in weight-loss treatments, has entered the Moroccan market through a partnership between Danish pharmaceutical company Novo Nordisk and ...

Less than three months into his tenure, Novo Nordisk’s new CEO has undeniably left his mark on the company, launching a ...

Adults with obesity lose more weight with semaglutide than with placebo (a sham medication). However, the risk of unwanted events is probably higher than with placebo after 24 months. Semaglutide ...

An experimental GLP-1/glucagon (GCP) dual receptor agonist from Eli Lilly and its Chinese partner Innovent has bested Novo Nordisk’s reigning GLP-1 semaglutide in a phase 3 study across both b | ...

Semaglutide lowered the risk of major adverse cardiovascular events across all body weight and waist circumference levels in ...